WHAT TO KEEP IN MIND
Interest is not proof.
All four peptides remain investigational for many proposed uses, and much of the research is laboratory, animal, or early stage. BPC 157 human evidence remains limited. TB 500 evidence must remain distinct from broader thymosin beta 4 research. KPV evidence remains limited and largely preclinical. GHK CU evidence varies by research area and delivery method. Research overlap does not prove that combining these products creates a stronger or safer outcome.



